Principles of Signal Detection. Pia Caduff-Janosa MD Annual Course May 2013

Similar documents
Monitoring Vaccines Introduction. Pia Caduff-Janosa MD May 2013

TITLE: SAFE USE OF MEDICINES IN ZANZIBAR A

Regulatory Aspects of Pharmacovigilance

A Data Mining Approach for Signal Detection and Analysis

Automatic extraction of adverse drug reaction terms from medical free text

Key Elements in Adverse Drug Interaction Safety Signals

The Logic of Causality. Dr Ruth Savage With acknowledgements to Professor Ralph Edwards

Principles of signal detection. Marie Lindquist

Active TB drug-safety management & monitoring

PHARMACOVIGILANCE: WHEN ADVERSE DRUG EVENTS OCCUR. Bartlomiej Piechowski-Jozwiak, MD Rabih Dabliz, Pharm.D., FISMP

WHO-ART. Magnus Wallberg. November 24 th 2009 Dar Es Salaam, Tanzania.

Existing WHO work on Medicines Safety & Safe Use. Department of Essential Medicines and Health Products World Health Organization

Global Vaccine Safety Initiative Activities Portfolio

Applies to: Signal and Incident Management Service in the Inspections, Human Medicines Pharmacovigilance and Committees division

A method for data driven exploration to pinpoint key features in medical data and facilitate expert review

Reporting Patterns Indicative of Adverse Drug Interactions

Adverse Events Monitoring (aka Pharmacovigilance)

A practical handbook on the pharmacovigilance of antiretroviral medicines

1. Introduction to Pharmacovigilance

Global Vaccine Safety Initiative Portfolio activities

PHARMACOVIGILANCE GLOSSARY

Pharmacovigilance. Dr. Anjan Adhikari Associate Professor Department of Pharmacology R G Kar Medical College & Hospital Kolkata

A practical handbook on the pharmacovigilance of antiretroviral medicines

Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

A Proof-of-Concept Evaluation of Adverse Drug Reaction Surveillance in Electronic Health Records

Adverse Event Reporting Programme for Veterinary Medicines

Pharmacovigilance in HIV/AIDS Public Health Programmes: Luxury or Priority?

Use of Secondary Population- Based Databases to Evaluate the Safety of Medications

The impact of age and sex on the reporting of cough and angioedema with renin angiotensin system inhibitors: a case/ noncase study in VigiBase

8.0 ADVERSE EVENT HANDLING

International Journal of PharmTech Research CODEN (USA): IJPRIF, ISSN: Vol.8, No.1, pp , 2015

Routine signal detection and statistical tools on paediatrics

Experience of Belarus in introducing enhanced pharmacovigilance for linezolid in treatment of M/XDR-TB

Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction

ADVERSE DRUG REACTION REPORTS IN MALAYSIA: COMPARISON OF CAUSALITY ASSESSMENTS

Practicality of direct Reporting Of ADRs by Patients

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

NEWSLETTER October The Pharmacovigilance Risk Assessment Committee July (PRAC) Meeting

Safety monitoring of vaccines. Jeremy Labadie MD vaccine safety specialist

Adverse Drug Reactions (ADRs) Outline

WHO Strategy for Collecting Safety Data in Public Health Programmes: Complementing Spontaneous Reporting Systems

Drugs Regulatory Unit Ministry of Health PHARMACOVIGILANCE GUIDELINES

Clinical Informatics and Clinician Engagement. Martin Sizemore, Chief Data Officer Wake Forest Baptist Health May 3, 2017

Increasing the uptake of MMR in London: executive summary of findings from the social marketing project, November 2009

Supplementary Appendix

Adverse Experience Reporting

Recommendations of fourth meeting of the WHO Advisory Committee on Safety of Medicinal Products 26 and 27 February 2007

Biobank & Bio-PIN. Dr. J.J. Nietfeld

This document outlines the clinical risks assessed as AFAP within INRstar.

National Lung Cancer Audit outlier policy 2017

Course: SPPA 331 Basic Audiology Fall 2006 M,W,F - 9:30 a.m. BH Semester Credits

Littlejohn, S. W. (2001). Theories of human communication. Belmont, CA: Wadsworth. ["Theories of Message Reception and Processing" pp.

Idelalisib and Progressive Mul2focal Leukoencephalopathy. ISoP Annual Mee-ng 2016 R.E.Chandler and P. Caduff- Janosa

Methods in Pharmacovigilance

Signal detection at Lareb

Benefit-Harm assessments

Risk Management Plans Review of Experience

Statistical methods for knowledge discovery in adverse drug reaction surveillance

Data retrieval using the new SMQ Medication Errors

1.1. Bisphosphonates and stomatitis

Switzerland - still a special country?

SAE håndtering i protokol CC MM-001

Lecture 2. Key Concepts in Clinical Research

JUNE 2011 Vol.29 No.6 CME 247

Chapter 6 PHARMACOVIGELANCE. M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Nelfinavir: Barbados Experience

Serious Adverse Event (SAE) Form Clinical Trials

The cost of the double burden of malnutrition. April Economic Commission for Latin America and the Caribbean

CDC s experience: A case study of communications during a foodborne outbreak response

When a Cluster Becomes an Outbreak The Multistate Perspective

Alcohol Relapse Prevention Using Mobile Technology

Scientific conclusions

Activa RC Neurostimulator MEDTRONIC DBS CHARGING EXPERIENCE

Regression and causal analysis. Harry Ganzeboom Research Skills, December Lecture #5

1.1. Lenalidomide and (aggravation of) psoriasis

Course: SPPA 331 Basic Audiology Fall 2011 M,W,F - 9:30 a.m. BH Semester Credits

A Framework for Conceptualizing, Representing, and Analyzing Distributed Interaction. Dan Suthers

Conduct Rigorous and Scientific Research. Chang Xu Department of Computer Science and Technology Nanjing University Sep 21, 2018

Radon: A Behavioural as well as a Technical & Health Challenge.

Time series disturbance detection for hypothesis-free signal detection in longitudinal observational databases

Drug Safety Monitoring in a Prepandemic and Pandemic Avian Flu Mass Vaccination Scenario

Adverse drug reactions. Prof. dr. Jolanta Gulbinovič

Sarah Watson 1 Rebecca E. Chandler. Birgitta Grundmark 1,3 Alem Zekarias

Special guidelines for preparation and quality approval of reviews in the form of reference documents in the field of occupational diseases

Vaccine Safety: the risk of undermining our successes at the global level

Version Effective date Changes Prepared By CPR + AED

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Adverse Events Following. Kevin Connolly Waterford, Aug. 25, 2016

Interim WHO guidance for the surveillance of human infection with swine influenza A(H1N1) virus

PROTECT Alcohol labelling policies to protect young people

Review of public information programmes to enhance home radon screening uptake and home remediation

Influenza Vaccine Safety Monitoring Update

A regulatory perspective What do I want to know?

Adverse Outcomes After Hospitalization and Delirium in Persons With Alzheimer Disease

D R U G A L E R T CLASS 4 MEDICINES DEFECT INFORMATION Caution in Use Distribute to Pharmacy, Hospital, GP, Ward and Clinic Level

Valproic Acid and Fatalities in Children: A Review of Individual Case Safety Reports in VigiBase

The Bio-PIN: J.J. Nietfeld, PhD UMC Utrecht. Prof. J.-E. Litton, PhD. A tool that can solve biobanking problems INTRESCO. J.J.

Disease Surveillance. Soili Larkin & Joshna Mavji

Overview of Study Designs in Clinical Research

Transcription:

Principles of Signal Detection Pia Caduff-Janosa MD Annual Course May 2013

Outline What is a signal? Signal sources Triggers Assessment of potential risk Signal evaluation Outcome 2 Pia Caduff-Janosa, Uppsala Monitoring Centre

What is a signal? Reported information on a possible causal relationship between an adverse event and a drug, the relationship being unknown or incompletely documented previously. Usually more than a single report is required to generate a signal, depending upon the seriousness of the event and the quality of the information. The publication of a signal usually implies the need for some kind of review or action. 3 Pia Caduff-Janosa, Uppsala Monitoring Centre

Signal sources Individual Case Safety Reports Clinical studies Literature WHO Programme-UMC Scientific conferences Drug Regulatory Authorities Media 4 Pia Caduff-Janosa, Uppsala Monitoring Centre

5 Pia Caduff-Janosa, Uppsala Monitoring Centre

Signal bells...... when should they start ringing? 6 Pia Caduff-Janosa, Uppsala Monitoring Centre

Triggers ADR reported is unexpected Fatal outcome or life threatening course Specific ADRs SJS, TEN Agranulocytosis Cluster Unusual aspects of expected ADRs 7 Pia Caduff-Janosa, Uppsala Monitoring Centre

Action Signal confirmed? Case series further information Individual case safety report 10 Pia Caduff-Janosa, Uppsala Monitoring Centre 10

How many reports make a signal? 3 index cases Completely documented No or only minimal confounders Positive de-/rechallenge 11 Pia Caduff-Janosa, Uppsala Monitoring Centre 11

Further information? What do we know about the drug itself? What do we know about the way it is used? What do we know about similar drugs (class effects)? Is there a reasonable causal relationship between drug and reaction in our case reports? Signal assessment = causality assessment?? 12 Pia Caduff-Janosa, Uppsala Monitoring Centre

Signal assessment Labelling national and international Case series in databases? National database VigiBase/VigiLyze Literature 13 Pia Caduff-Janosa, Uppsala Monitoring Centre 13

Signal assessment Small database Mostly case series and assessment of ICSRs Large database Automated search for disproportionalities Case series 14 Pia Caduff-Janosa, Uppsala Monitoring Centre

UMC signalling process WHO db VigiBase National PV Centres Pharma Company Data mining Disproportionality measure (IC) Triage algorithms UMC review Literature check etc 15 Pia Caduff-Janosa, Uppsala Monitoring Centre Not (yet) signal Clinical assessment UMC + Review Panel

Data analysis single case Demographic data Medical history Chronology Risk factors Differential diagnosis De-/Rechallenge Concomitant medication Other confounders/bias 16 Pia Caduff-Janosa, Uppsala Monitoring Centre 16

Signal assessment is about patterns Who is at risk? Are there patient specific risk factors? Are there drug specific risk factors? Is there a geographical pattern? Does the ADR follow a pattern? 17 Pia Caduff-Janosa, Uppsala Monitoring Centre

Signal assessment There is no magic button... 18 Pia Caduff-Janosa, Uppsala Monitoring Centre

Signal assessment is about... Hard and patient intellectual work 19 Pia Caduff-Janosa, Uppsala Monitoring Centre

...and Decision making 20 Pia Caduff-Janosa, Uppsala Monitoring Centre

Dilemma A signal should be identified as soon as possible to allow early warning but should be documented as well as possible (credibility) When is there ENOUGH evidence? 21 Pia Caduff-Janosa, Uppsala Monitoring Centre 21

Risk minimization Action taken (mostly) by Regulatory Authorities with the aim of keeping a positive benefit risk balance 22 Pia Caduff-Janosa, Uppsala Monitoring Centre

Potential risk Exposed population (size, sensitive populations) Essential medicinal product Seriousness and severity of ADR Avoidable ADR? Rapid increase of number of reports Public impact and perception 23 Pia Caduff-Janosa, Uppsala Monitoring Centre

The risk potential defines the next move 24 Pia Caduff-Janosa, Uppsala Monitoring Centre

If the risk is assessed as very high, risk minimizing actions might be justified even if the signal is not (yet) confirmed 25 Pia Caduff-Janosa, Uppsala Monitoring Centre

More on this......on Monday May 27th @ 8.30 am 26 Pia Caduff-Janosa, Uppsala Monitoring Centre

Take home messages A signal is a work hypothesis that needs to be confirmed or refuted Signal assessment is a dynamic process Signal detection is a lifelong process for every medicinal product Well documented ICSRs (index cases) are one of the most precious elements in signal detection and assessment Signal assessment is intellectual work 27 Pia Caduff-Janosa, Uppsala Monitoring Centre 27

28 Pia Caduff-Janosa, Uppsala Monitoring Centre Questions?

Uppsala Monitoring Centre Box 1051 SE-751 40 Uppsala, Sweden Visiting address: Bredgränd 7, Uppsala tel +46 18 65 60 60 fax +46 18 65 60 88 website www.who-umc.org 29 Pia Caduff-Janosa, Uppsala Monitoring Centre